Quarterly ResultAug 6, 2026, 08:53 AM
Barinthus Bio Q2 Net Loss $10.6M; Merger & Clinical Trial Updates
AI Summary
Barinthus Biotherapeutics reported a net loss of $10.6 million for the second quarter of 2026. The company announced continued progress on its proposed combination with Clywedog Therapeutics Inc., with the merger expected to complete in the second half of 2026. Additionally, Barinthus Bio completed enrollment in the Phase 1 AVALON trial for VTP-1000 in celiac disease, with topline data anticipated in Q4 2026. The company also received an extension from Nasdaq to regain compliance with listing requirements.
Key Highlights
- Q2 2026 net loss attributable to shareholders was $10.6 million.
- Cash, cash equivalents, and restricted cash totaled $59.6 million as of June 30, 2026.
- Research and development expenses were $3.9 million in Q2 2026.
- General and administrative expenses were $7.1 million in Q2 2026.
- Completed enrollment in the Phase 1 AVALON trial for VTP-1000 in celiac disease.
- Proposed merger with Clywedog Therapeutics Inc. is progressing, expected to close in H2 2026.
- Received Nasdaq extension until December 28, 2026, to regain bid price compliance.
Price Impact
More from BRNS